MassBio's Strategic Plan

Archive for the ‘Twitter Chats’ Category

Defining Value

MassBio continued its #Impact2020 Twitter Chat Series with a discussion on defining value. Impact 2020 examines the balance between value-based, evidence-based medicine in the era of healthcare reform and the uncertainty it creates for investors and entrepreneurs who seek reward for innovation and risk-taking. Value creation is, and will continue to be critical to success in the life sciences industry.

In the chat, we discussed how key stakeholders define value and how companies can work to demonstrate value in today’s healthcare system.

Click here to check out the conversation!

defining value screenshot

Advertisements

Rare Disease Research

MassBio continued its #Impact2020 Twitter Chat Series with a discussion of rare disease research today and tomorrow, in Massachusetts and beyond.

There are approximately 30 million people living with a rare disease in the USA, between 27 and 36 million in the EU, and collectively around the globe, the rare disease community is estimated to include 350 million people. There are more than 7,000 rare diseases, many of them with no treatment or cure.

Many rare disease therapies are under development in Massachusetts and these leading researchers are pushing for accelerated approval pathways.

In this Twitter chat, we discussed the current state of rare disease research, the clinical and regulatory challenges for rare disease research, and how patients and patient advocates are making a difference.

Click here to read the conversation!

rare twitter chat

Patient Advocacy for the Future

MassBio launched Impact 2020 on April 3, 2014. The report lays a path forward for the future of life sciences in Massachusetts, and at the heart of it all is the patient, so we decided to host a Twitter Chat about patients and patient advocacy.

Patients and patient advocates have historically played a very important role in shaping the biotechnology industry and its innovative therapies. In the future, as the healthcare system undergoes a major shift, patients will play an even more critical role.

To ensure innovative, valuable therapies make it to patients as Massachusetts and the nation implement healthcare cost containment measures, it is critical that the patient voice is not only heard, but amplified.

For this April 15 chat, we tweeted from the Life Sciences Foundation’s Voices Carry event where we heard patient advocacy perspectives from David Meeker, John Maraganore, Bill Haseltine, and Joan Finnegan Brooks.

Click here to check out the conversation!

Storify Screenshot

Early-Stage Funding, New Models for Success

Building buzz for Impact 2020: The MassBio Strategic Report, we continued our #Impact2020 Twitter Chat Series last night. In the chat we focused on the evolution & future of early-stage funding in life sciences with moderator John Hallinan, Chief Business Officer at MassBio, and guest moderator David Berry, Partner at Flagship Ventures.

From pharma-based venture funds to advocacy group-directed research to crowd-funding, we’re in the midst of a sea change in how emerging biotechs find funding and address capital challenges. The IPO window reopened in 2013 but how long can we expect it to stay open? With a significant decline in seed stage funding, are Massachusetts’ good ideas being funded? How do we continue to support fledgling companies that need startup money for early research or proof-of-concept?

Click here to check out the conversation!

Storify Screenshot!